Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb CoLIM:BMY 56 Return-on-Tangible-Asset is 22.50% as of Mar. 2026, which is 53% above its 10-year median of 14.75. GuruFocus rates LIM:BMY with a GF Score™ of 56/100 and a GF Value™ of $51.53 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 88.48% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bristol-Myers Squibb Co's annualizedNet Income for the quarter that ended in Mar. 2026 was $10,708 Mil. Bristol-Myers Squibb Co's average total tangible assets for the quarter that ended in Mar. 2026 was $47,588 Mil. Therefore, Bristol-Myers Squibb Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 22.50%.
The historical rank and industry rank for Bristol-Myers Squibb Co's Return-on-Tangible-Asset or its related term are showing as below:
LIM:BMY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -20.5 Med: 14.75 Max: 18.7
Current: 14.62
During the past 13 years, Bristol-Myers Squibb Co's highest Return-on-Tangible-Asset was 18.70%. The lowest was -20.50%. And the median was 14.75%.
LIM:BMY's Return-on-Tangible-Asset is ranked better than 88.48% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs LIM:BMY: 14.62
Bristol-Myers Squibb Co (LIM:BMY) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bristol-Myers Squibb Co Return-on-Tangible-Asset Related Terms
Bristol-Myers Squibb Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bristol-Myers Squibb Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Return-on-Tangible-Asset Chart
LIM:BMY vs PFE, GILD, AMGN: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 22.50% mean?
Bristol-Myers Squibb Co (LIM:BMY) has a Return-on-Tangible-Asset of 22.50% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bristol-Myers Squibb Co and its competitors. This is 53% above median its historical median of 14.75. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #116 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 11.5%.
Is Bristol-Myers Squibb Co's Return-on-Tangible-Asset too high?
Bristol-Myers Squibb Co's current Return-on-Tangible-Asset of 22.50% is 53% above median its 10-year median of 14.75. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Bristol-Myers Squibb Co's value of 22.50% is 614.3% above this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #116 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Return-on-Tangible-Asset compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #116 out of 1007 companies for Return-on-Tangible-Asset. This places Bristol-Myers Squibb Co in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Bristol-Myers Squibb Co's value of 22.50% is 614.3% above this benchmark. While the company's 10-year median is 14.75 vs. the industry median of 3.15, Bristol-Myers Squibb Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Return-on-Tangible-Asset of 22.50% is 614.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Return-on-Tangible-Asset is 22.50%, which is 53% above median its own 10-year median of 14.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $51.53, compared to a current price of $56.98 — trading 10.6% above its estimated fair value. The current Return-on-Tangible-Asset is 22.50%, which is 53% above median its 10-year median of 14.75 and 614.3% above the Drug Manufacturers industry median of 3.15. Bristol-Myers Squibb Co's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current Return-on-Tangible-Asset is 22.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $56.98 is trading 10.6% above its estimated GF Value™ of $51.53.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for LIM:BMY:
Return-on-Tangible-Asset: 22.50% (53% above median its 10-year median of 14.75)
GF Value™: $51.53 vs. price of $56.98 (10.6% above fair value)
Industry Position: 614.3% above the Drug Manufacturers median (#116 of 1007)
No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
56GF Score
Get the complete analysis for LIM:BMY
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIM:BMY has been successfully added to your 
